TRK-IN-17
TRK-IN-17 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5) . TRK-IN-17 has the potential for the research of cancer diseases (extracted from patent WO2021148807A1, compound 3) [1].
Product Specifications
CAS Number
2409544-80-3
UNSPSC
12352005
Target
Trk Receptor
Type
Reference compound
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/trk-in-17.html
Solubility
10 mM in DMSO
Smiles
CCN/C(C1=CN=C2C=CC(N3C[C@H](C[C@@H]3C4=CC(F)=CC(SC)=C4)F)=NN12)=N\C#N
Molecular Formula
C21H21F2N7S
Molecular Weight
441.50
References & Citations
[1]Nicola ROBAS, et al. Pharmaceutical compositions and their uses. Patent WO2021148807A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Beta crystallin S (CRYGS) (NM_017541) Human Recombinant Protein
